All News

Found 3,475 articles

• Sorrento Therapeutics, Inc. Announces Confidential Submission Of Draft Registration Statement For Initial Public Offering (IPO) Of Its Wholly-Owned Subsidiary Ark Animal Health With The SEC

  6/23/2014

• Sorrento Therapeutics, Inc. To Present At Biotechnology Industry Organization (BIO) Business Forum

  6/23/2014

• ImmunoGen, Inc. Announces Preclinical Findings For IMGN779, A Potential Treatment For Acute Myeloid Leukemia

  6/16/2014

• Sorrento Therapeutics, Inc. Announces Underwriters' Exercise Of Over-Allotment Option

  6/13/2014

• ImmunoGen, Inc. Announces Favorable STARLYTE Phase II Clinical Data With Sanofi’s SAR3419 In Diffuse Large B-Cell Lymphoma

  6/2/2014

• Agensys, Inc. And Sea Lane Biotechnologies, LLC Sign Commercial License Agreement For Antibodies Generated Using ConCIRT Libraries

  6/2/2014

• Sorrento Therapeutics, Inc. To Present At Jefferies and Co. 2014 Global Healthcare Conference

  6/2/2014

• Wilex AG Sends Back Some Promising Drugs To UCB, Inc. In Effort To Stay Alive

  5/22/2014

• ADC Therapeutics To Move Antibody Drug Conjugate ADCT-401 For Prostate Cancer Into Human Clinical Trials With Partner MedImmune

  5/19/2014

• Meditope Biosciences Appoints C. Dan Dumitru As Vice President Of Translational Research

  5/19/2014

• Sorrento Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock

  5/15/2014

• ImmunoGen, Inc. Announces Clinical Data Presentations At Upcoming 50th Annual Meeting Of American Society of Clinical Oncology

  5/15/2014

• Immunomedics, Inc. To Present Updated Phase 2 Results From Antibody-Drug Conjugate Programs At 2014 American Society of Clinical Oncology

  5/15/2014

• Sorrento Therapeutics, Inc. Announces Transfer Of Orphan Drug Designation Sponsorship for Intrathecal Resiniferatoxin From National Institutes of Health (NIH)

  5/13/2014

• Novozymes Biopharma To Offer Drug-Albumin Conjugation Platform In Collaboration With Thiologics

  5/13/2014

• ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences

  5/6/2014

• Ambrx, Inc. And Zhejiang Hisun Pharmaceutical To Collaborate On The Development And Commercialization Of Bispecifics For Cancer

  4/29/2014

• ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2014 Financial Results And Provides Corporate Update

  4/25/2014

• ImmunoGen, Inc. Announces Conference Call To Discuss Its Third Quarter Fiscal Year 2014 Financial Results

  4/18/2014

• Oxford Finance And Silicon Valley Bank Expand Existing Senior Credit Facility With Sorrento Therapeutics, Inc. To $12.5 Million

  4/17/2014